SMART Therapy: Making a Science-Based Choice (AAN)

Price: FREE for members and non-members

Session recorded on April 18, 2023
Speaker: Len Bacharier, MD

SMART (Single Maintenance and Reliever Therapy) allows people with asthma to use just one medication for both maintenance and reliever therapy. Both NAEPP and GINA guidelines identify the role of this therapy in asthma management.  Despite this, many providers are unfamiliar with the basis of this recommendation or how to implement it. In this webinar, attendees will learn how to implement MART in patients with asthma and how to develop action plans using MART.

Viewers can earn credit by completing the posttest questions.

This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers
Allied Health Professionals

Learning Objectives

Upon completion of this activity, learners should be able to:

  1. Explain the basis of anti-inflammatory reliever therapy, both as MART and as a reliever in mild asthma.
  2. Describe how to implement MART in patients with asthma.
  3. Develop action plans using MART.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

All identified conflicts of interest have been mitigated.

The individuals listed below disclose the following financial relationships:

Len Bacharier, MD

Advisor: Sanofi/Regeneron, GlaxoSmithKline, AstraZeneca, Avillion, DBV Tech, Vertex, OM Pharma, Recludix

Consultant: Sanofi/Regeneron, AstraZeneca, Avillion, Genentech

Speaker: Sanofi/Regeneron

Researcher: Sanofi/Regeneron

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.